ALX Oncology’s (ALXO) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of ALX Oncology (NASDAQ:ALXO) in a research report sent to investors on Friday morning,Benzinga reports. Cantor Fitzgerald also issued estimates for ALX Oncology’s FY2025 earnings at ($2.21) EPS.

Other analysts have also recently issued research reports about the stock. HC Wainwright reduced their target price on shares of ALX Oncology from $25.00 to $5.00 and set a “buy” rating for the company in a research note on Friday. Jefferies Financial Group downgraded shares of ALX Oncology from a “buy” rating to a “hold” rating and reduced their price objective for the company from $12.00 to $2.00 in a research report on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, ALX Oncology presently has an average rating of “Moderate Buy” and an average price target of $3.50.

ALX Oncology Price Performance

Shares of NASDAQ ALXO opened at $1.52 on Friday. The stock has a fifty day moving average price of $1.62 and a 200 day moving average price of $2.36. ALX Oncology has a 1-year low of $1.19 and a 1-year high of $17.83. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The company has a market cap of $79.91 million, a PE ratio of -0.51 and a beta of 0.98.

Insider Activity

In related news, Director Rekha Hemrajani acquired 30,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were purchased at an average price of $1.55 per share, with a total value of $46,500.00. Following the completion of the acquisition, the director now owns 33,000 shares in the company, valued at approximately $51,150. This represents a 1,000.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 14,443 shares of company stock worth $23,309 in the last 90 days. 33.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ALX Oncology

Hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC increased its stake in ALX Oncology by 243.6% in the 3rd quarter. Barclays PLC now owns 59,502 shares of the company’s stock valued at $107,000 after purchasing an additional 42,185 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in ALX Oncology during the second quarter worth $1,834,000. GSA Capital Partners LLP acquired a new stake in ALX Oncology in the third quarter valued at $88,000. Marshall Wace LLP increased its position in shares of ALX Oncology by 423.0% in the second quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock valued at $3,833,000 after buying an additional 514,133 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after buying an additional 6,888 shares during the last quarter. 97.97% of the stock is currently owned by institutional investors and hedge funds.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.